Mithra Pharmaceuticals S.A.

AGM Information • Nov 23, 2023

CONFIDENTIAL DRAFT

Mithra announces results of the 23 November 2023 Extraordinary General Meeting

• The issuance of warrants and investment options were approved, enabling Armistice Capital to proceed, under certain conditions, to make capital increases in the Company

Liege, Belgium, 23 November 2023 – 17:45 CET – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA, the "Company"), a company dedicated to Women's Health, announces the results of its Extraordinary General Meeting (EGM) held today. The meeting was held at Mithra's CDMO facility based in Flémalle, Belgium on 23 November 2023 as from 14:00 CET.

The items on the agenda, shared on 6 November 2023, in the Convening Notice and meeting Agenda documents, of the EGM included: (1) a review of the special report prepared by the board of directors regarding the proposal to renew the authorised capital, (2) the renewal of the authorization to the board of directors to increase the capital within the framework of the authorized capital (3) the renewal of the authorization to the board of directors to increase the capital within the framework of the authorized capital, even after the FSMA has notified the Company of a public takeover bid on the Company's shares, (4) the communication, consideration and discussion of reports concerning a proposed capital increase related to the Highbridge/Whitebox agreements, (5) the resolution to increase the Company's share capital, related to the Highbridge/Whitebox agreements, (6) the communication, consideration and discussion of reports concerning the proposed issuance of subscription rights, (7) the proposition to issue 10,000,000 warrants, which may be exercised at a price of EUR 2.25 per new share -- with a 5-year term, and, (8) the proposition to issue 10,000,000 investment options, which may be exercised at a price of EUR 2.25 per new share -- with an 18-month term.

Shareholders voted positively on all key points proposed at the EGM.

David Horn Solomon, Mithra's Chief Executive Officer added, "We are pleased that shareholders voted to support all points covered during this latest EGM, ensuring that Mithra is provided with the capital, under the previously agreed upon terms, to enable us to continue our growth and transformation initiatives."

For more information, please contact:

Mithra Pharmaceuticals SA Alex Sokolowski, PhD Head of Investor Relations investorrelations@mithra.com +32 (0)4 349 28 22

Frédérique Depraetere Communications Director info@mithra.com +32 (0)4 349 28 22

CONFIDENTIAL DRAFT

About Mithra

Mithra Pharmaceuticals SA (Euronext: MITRA) is a Belgian biopharmaceutical company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra explores the potential of the unique native estrogen estetrol in a wide range of applications in women health and beyond. After having successfully launched the first estetrol-based product in 2021, the contraceptive pill ESTELLE® , Mithra is now focusing on its second product DONESTA® , the next-generation hormone therapy. Mithra also offers partners a complete spectrum of solutions from early drug development, clinical batches and commercial manufacturing of complex polymeric products (vaginal ring, implants) and complex liquid injectables and biologicals (vials, pre-filled syringes or cartridges) at its technological platform Mithra CDMO. Active in more than 100 countries around the world, is headquartered in Liège, Belgium. www.mithra.com

ESTELLE® and DONESTA® are registered trademarks of Mithra Pharmaceuticals or one of its affiliates.

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

News Alerts

Subscribe to our mailing list on investors.mithra.com to receive press releases by email or follow us on social media: Linkedin • X • Facebook